Drug intelligence / Profile preview

TJC0545

Development stage: Preclinical
Lead developer: TaiwanJ Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

TJC0545 is a small molecule histone deacetylase (HDAC) inhibitor currently in preclinical development by TaiwanJ Pharmaceuticals. As an epigenetic modulator, it is designed to regulate gene expression by inhibiting the removal of acetyl groups from histone proteins, which typically leads to a more open chromatin structure and altered transcriptional activity. TJC0545 is part of TaiwanJ's core HDAC technology platform, which focuses on developing innovative therapies for unmet medical needs, although specific therapeutic indications have not yet been publicly disclosed.

Targets

HDAC (HDAC family)

Beyond the preview

Go deeper on TJC0545.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJC0545.

Explore the full profile